An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.

被引：1
|
作者：
Decoster, Lore
Cappoen, Nadia
Aftimos, Philippe Georges
Raicevic, Gordana
Rolfo, Christian Diego
Rottey, Sylvie
Duhoux, Francois P.
Collignon, Joelle
Hebrant, Aline
Vandenbulcke, Marc
De Greve, Jacques
机构：
[1] UZ Brussel, Brussels, Belgium
[2] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
[3] Belgian Soc Med Oncol, Brussels, Belgium
[4] Univ Antwerp Hosp, Edegem, Belgium
[5] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium
[6] Clin Univ St Luc, King Albert II Canc Inst, Dept Med Oncol, Brussels, Belgium
[7] Catholic Univ Louvain, Inst Rech Expt & Clin Pole MIRO, Brussels, Belgium
[8] CHU Sart Tilman, Liege, Belgium
[9] Wetenschappelijk Inst Volksgezondheid Belgie, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS2615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2615
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial
    Adams, Richard
    Brown, Ewan
    Brown, Louise
    Butler, Rachel
    Falk, Stephen
    Fisher, David
    Kaplan, Richard
    Quirke, Phil
    Richman, Susan
    Samuel, Leslie
    Seligmann, Jenny
    Seymour, Matt
    Shiu, Kai Keen
    Wasan, Harpreet
    Wilson, Richard
    Maughan, Tim
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (03): : 162 - 171
  • [32] A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME).
    Baselga, Jose
    Hegg, Roberto
    Vidal Losada, Maria
    Vidaurre, Tatiana
    Lluch, Ana
    Petrakova, Katerina
    Mann, Helen
    Ghiorghiu, Serban
    Stuart, Mary
    Landers, Donal
    Thress, Kenneth
    Klinowska, Teresa
    Cortes, Javier
    CANCER RESEARCH, 2013, 73 (08)
  • [33] Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial.
    Harding, James J.
    Cleary, James M.
    Quinn, David I.
    Brana, Irene
    Moreno, Victor
    Borad, Mitesh J.
    Loi, Sherene
    Spanggaard, Iben
    Park, Haeseong
    Ford, James M.
    Arnedos, Monica
    Stemmer, Salomon M.
    De La Fouchardiere, Christelle
    Ramirez, Santiago Viteri
    Fountzilas, Christos
    Zhang Jie
    Xu Feng
    Lalani, Alshad S.
    Piha-Paul, Sarina Anne
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [34] Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
    Dziadziuszko, Rafal
    Smit, Egbert F.
    Dafni, Urania
    Wolf, Juergen
    Wasag, Bartosz
    Biernat, Wojciech
    Finn, Stephen P.
    Kammler, Roswitha
    Tsourti, Zoi
    Rabaglio, Manuela
    Ruepp, Barbara
    Roschitzki-Voser, Heidi
    Stahel, Rolf A.
    Felip, Enriqueta
    Peters, Solange
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1086 - 1094
  • [35] A phase Ⅰ study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Pin Zhang
    Lin Wang
    Yueying Zhen
    Zhihong Wang
    Hesheng Zhang
    Richard Jones
    Binghe Xu
    ChineseJournalofCancerResearch, 2024, 36 (01) : 46 - 54
  • [36] ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
    Shpektor, Diana
    Dargahi, Daryanaz
    Samiotakis, Antonios
    Wienke, Sara
    Livernois, Ali
    Yablonovitch, Arielle
    Yalamanchili, Geethika
    Gartner, Elaina
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2023, 83 (08)
  • [37] A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
    Hong, M. H.
    Spira, A. I.
    Lee, K. H.
    Cho, E. K.
    Han, J-Y.
    Shim, B. Y.
    Lee, J-S.
    Kao, S. C-H.
    Kim, S-W.
    Khattak, A.
    Patel, M.
    Xu, R.
    Wang, J.
    Ariazi, E.
    Daemen, A.
    Maneval, E. Chow
    Multani, P. S.
    Patel, R.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [38] Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
    Gadgeel, Shirish M.
    Lew, Danika L.
    Synold, Timothy W.
    LoRusso, Patricia
    Chung, Vincent
    Christensen, Scott D.
    Smith, David C.
    Kingsbury, Laura
    Hoering, Antje
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1089 - 1096
  • [39] Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
    Shirish M. Gadgeel
    Danika L. Lew
    Timothy W. Synold
    Patricia LoRusso
    Vincent Chung
    Scott D. Christensen
    David C. Smith
    Laura Kingsbury
    Antje Hoering
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1089 - 1096
  • [40] Phase Ib trial of varlitinib plus weekly paclitaxel in EGFR/HER2 co-expressing advanced gastric cancer (AGC)
    Sang, Yunbeom
    Jung, Minkyu
    Kim, Hyo Song
    Kang, Beodeul
    Lee, Choong-kun
    Chung, Hyun Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345